Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00986154 · ClinicalTrials.gov registry record · Phase 3
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,292
- Enrollment target
NCT00986154 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 8,292 participants.
The verdict
NCT00986154, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,292 participants
- Enrollment target
Study Summary
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
Interventions
- DRUG warfarin
- DRUG edoxaban tosylate(DU-176b)
- DRUG low molecular weight heparin/unfractionated heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,292 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00986154
The ClinicalTrials.gov registry entry for NCT00986154 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which warfarin is the first listed.
NCT00986154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00986154 about?
NCT00986154 is a clinical study titled "Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).". Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
What is the current status of trial NCT00986154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,292 participants. The study started on 2009-10. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00986154?
The interventions under investigation include: warfarin (DRUG), edoxaban tosylate(DU-176b) (DRUG), low molecular weight heparin/unfractionated heparin (DRUG).
Who is sponsoring clinical trial NCT00986154?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.